These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30214486)

  • 21. Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.
    Kantarci OH; Zeydan B; Atkinson EJ; Conway BL; Castrillo-Viguera C; Rodriguez M
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31848231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.
    Liu Y; Morgan C; Hornung L; Tyry T; Salter AR; Agashivala N; Belletti DA; Kim E; Fox RJ; Cofield SS; Cutter GR
    J Neurol Sci; 2016 Mar; 362():121-6. PubMed ID: 26944131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
    Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
    Front Neurol; 2021; 12():699844. PubMed ID: 34497577
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early clinical markers of aggressive multiple sclerosis.
    Malpas CB; Manouchehrinia A; Sharmin S; Roos I; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Eichau S; Bergamaschi R; Sola P; Ferraro D; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Grand'Maison F; Ozakbas S; Van Pesch V; Granella F; Hupperts R; Pucci E; Boz C; Sidhom Y; Gouider R; Spitaleri D; Soysal A; Petersen T; Verheul F; Karabudak R; Turkoglu R; Ramo-Tello C; Terzi M; Cristiano E; Slee M; McCombe P; Macdonell R; Fragoso Y; Olascoaga J; Altintas A; Olsson T; Butzkueven H; Hillert J; Kalincik T
    Brain; 2020 May; 143(5):1400-1413. PubMed ID: 32386427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.
    Pan G; Simpson S; van der Mei I; Charlesworth JC; Lucas R; Ponsonby AL; Zhou Y; Wu F; Taylor BV
    J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1204-1211. PubMed ID: 27559181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.
    Baroncini D; Zaffaroni M; Moiola L; Lorefice L; Fenu G; Iaffaldano P; Simone M; Fanelli F; Patti F; D'Amico E; Capobianco M; Bertolotto A; Gallo P; Margoni M; Miante S; Milani N; Amato MP; Righini I; Bellantonio P; Scandellari C; Costantino G; Scarpini E; Bergamaschi R; Mallucci G; Comi G; Ghezzi A
    Mult Scler; 2019 Mar; 25(3):399-407. PubMed ID: 29363396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
    Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
    BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T;
    Neurology; 2017 Sep; 89(10):1050-1059. PubMed ID: 28794248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
    Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term evolution of multiple sclerosis disability in the treatment era.
    ; Cree BA; Gourraud PA; Oksenberg JR; Bevan C; Crabtree-Hartman E; Gelfand JM; Goodin DS; Graves J; Green AJ; Mowry E; Okuda DT; Pelletier D; von Büdingen HC; Zamvil SS; Agrawal A; Caillier S; Ciocca C; Gomez R; Kanner R; Lincoln R; Lizee A; Qualley P; Santaniello A; Suleiman L; Bucci M; Panara V; Papinutto N; Stern WA; Zhu AH; Cutter GR; Baranzini S; Henry RG; Hauser SL
    Ann Neurol; 2016 Oct; 80(4):499-510. PubMed ID: 27464262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the course of relapsing-remitting MS using longitudinal disability curves.
    Achiron A
    J Neurol; 2004 Sep; 251 Suppl 5():v65-v68. PubMed ID: 15549358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium.
    Kister I; Chamot E; Bacon JH; Cutter G; Herbert J;
    Mult Scler; 2011 Jun; 17(6):725-33. PubMed ID: 21270059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal disability curves for predicting the course of relapsing-remitting multiple sclerosis.
    Achiron A; Barak Y; Rotstein Z
    Mult Scler; 2003 Oct; 9(5):486-91. PubMed ID: 14582775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.